House of Representatives
Parliament House
Canberra ACT 2600
Dear Minister,
In response to the recent decision by the Health Minister to fund Botox treatment for axillary hyperhidrosis we have been prompted to submit this petition.
We would like to bring to your attention that palmar, facial, pedal and severe compensatory hyperhidrosis can have a negative social effect on a person’s life. Due to its high cost, Botox treatment is not accessible to many patients in Australia. We would like to petition for extended funding for Botox treatment for these conditions, rather than the current surgical treatments such as Endoscopic Thoracic Sympathectomy (ETS).
ETS has many common and undisclosed side-effects, including severe compensatory hyperhidrosis as found in reviews by FinOHTA [1] and 'ASERNIP-S' [2] . We wish to argue that the Medical Benefit Scheme (MBS) listing for ETS should be immediately suspended and urgently reviewed according to the strict guidelines set out by the Medical Services Advisory Committee (MSAC).
The level of endorsement (MBS listing) might impact on how the procedure is perceived by the public.
The recent MBS listing for Botox for axillary hyperhidrosis treatment sets out clear conditions and restrictions on its availability. There are no such conditions set out for the availability of the irreversible neurosurgical procedure, ETS.
We trust that decisions regarding funding are based on best available evidence regarding safety, effectiveness and cost effectiveness - and in this order. Available evidence however, cannot, and does not support the use of ETS as a safe procedure, and MSAC has never evaluated it.
In consideration of the provided supporting evidence, we hereby ask the Health Minister to:
Remove funding for Endoscopic Thoracic Sympathectomy and review the availability of this procedure, and the public’s exposure to it (including advertising, and infomercials), due to lack of reliable supporting evidence, and reports of adverse effects from the literature.
Extend funding for less harmful procedures (Botox and Ionthoporesis) for people with palmar, facial, pedal and severe compensatory hyperhidrosis. Patients with hyperhidrosis (and blushing) are evaluated by thoracic, vascular, general surgeons, with no training in treating or evaluating these conditions, nor in the field of Autonomic Nervous System (ANS). Patients should be evaluated and treated by specialists who are qualified to assess and treat these conditions (psychologists, dermatologists, neurologists).
Specify the alternative treatments patients have to trial before being able to undergo ETS - with sufficient funding, and time for these treatments to prove effectiveness.
Provide comprehensive and uniform information to all patients (including the internet) that describe the nature and consequences of this procedure, the foreseeability of complications, and recurrence, all based on high level evidence.
Clinical decision making can be tainted by bias, especially in the context of entrepreneurial medicine and elective procedures. Information provided to patients, especially in this setting can fall short of accepted standards of ‘informed consent’.
We look forward to your assistance in ensuring all Australians have a right to a fair medical system, where all surgical procedures have an objective trial, supporting evidence regarding safety, and alternative treatments are offered at a reasonable cost.
Sincerely yours,
[1] http://finohta.stakes.fi/NR/rdonlyres/A4F5CFC3-A6B4-43F5-8E2A-49689F3B7980/0/r026f.pdf
[2] http://www.surgeons.org/media/17412/RPT_2009-09-10_Evidence_essential_ETS.pdf
T(2)-T(3) ganglionectomy significantly decreases pulse rate and systolic blood pressure, reduces myocardial oxygen demand, increases left ventricular ejection fraction and prolongs Q-T interval. A certain loss of lung volume and decrease of pulmonary diffusion capacity for CO result from sympathectomy.
Histomorphological muscle changes and neuro-histochemical and biochemical effects have also been observed.
Clin Auton Res. 2003 Dec;13 Suppl 1:I40-4.
http://www.ncbi.nlm.nih.gov/pubmed/14673672
Several reports also demonstrate significantly lower heart rate increases during exercise in subjects who have undergone bilateral ISS [9–12] compared to pre-surgical levels. In spite of this high occurrence, recent reviews on the usual collateral effects of thoracic sympathectomy still do not include these possible cardiac consequences [6].
Eur J Cardiothorac Surg 2001;20:1095-1100
http://www.sciencedirect.com/science/article/pii/S1010794001010028